Clevidipine: A new intravenous option for the management of acute hypertension

Ndefo, Uche Anadu; Erowele, Goldina Ikezuagu; Ebiasah, Ruth; Green, Wendy
March 2010
American Journal of Health-System Pharmacy;3/1/2010, Vol. 67 Issue 5, p351
Academic Journal
Purpose. The pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, and place in therapy of clevidipine are reviewed. Summary. Clevidipine is a new lipophilic, short-acting, third-generation dihydropyridine calcium channel blocker (CCB) approved for use in the management of acute hypertension when oral agents are not feasible. It exerts its hemodynamic effects through selective arterial vasodilation without effects on the venous circulation. Clevidipine has a half-life of approximately two minutes after i.v. administration, resulting in very rapid onset and offset of antihypertensive action. Unlike many current i.v. antihypertensive agents that are metabolized by the kidneys or liver, clevidipine is metabolized in the blood and tissues and does not accumulate in the body. Clevidipine does not appear to inhibit or induce cytochrome P-450 isoenzymes. Several Phase III clinical trials have reported the clinical efficacy and safety of clevidipine in patients with severe hypertension and in cardiac surgical patients with perioperative hypertension. The most frequent adverse events reported in clinical trials of clevidipine were headache, nausea, and vomiting. Risk of rebound hypertension, especially in patients not transitioned from clevidipine to oral antihypertensive therapy after prolonged infusions, should be monitored for at least eight hours after the drug is discontinued. Conclusion. Clevidipine, a novel third-generation dihydropyridine CCB, has demonstrated efficacy and safety in patients with acute hypertension and preoperative, perioperative, and postoperative hypertension. While its short duration of action and short half-life are appropriate for use in acute settings, more information on its safety is needed to assess its appropriate use in therapy.


Related Articles

  • Pharmacokinetics of Deramciclane, a Novel Anxiolytic Agent, after Intravenous and Oral Administration. Huupponen, Risto; Paija, Outi; Salonen, Markku; Björklund, Harry; Rouru, Juha; Anttila, Markku // Drugs in R&D;2003, Vol. 4 Issue 6, p339 

    Background and objective: Deramciclane is a new compound that has shown anxiolytic effects in animal experiments and in human studies. The aim of this study was to determine the pharmacokinetic parameters of deramciclane after intravenous and oral administration, and its oral bioavailability....

  • Temperature Variations around Medication Cassette and Carry Bag in Routine Use of Epoprostenol Administration in Healthy Volunteers. Tamura, Yuichi; Nakajima, Yasuo; Ozeki, Yasushi; Ono, Tomohiko; Takei, Makoto; Yamamoto, Tsunehisa; Fukuda, Keiichi // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: According to several treatment guidelines, epoprostenol is an important treatment option for pulmonary arterial hypertension. However, the pharmacokinetic characteristics and poor stability of epoprostenol at room temperature make its administration challenging. We therefore studied...

  • Pharmacokinetics of amoxycillin and the rate of depletion of its residues in pigs. Martínes-Larrañaga, M.R.; Anadón, A.; Martínez, M.A.; Díaz, M.J.; Frejo, M.T.; Castellano, V.J.; Isea, G.; De La Cruz, C.O. // Veterinary Record: Journal of the British Veterinary Association;5/15/2004, Vol. 154 Issue 20, p627 

    Six pigs were used in a two-period crossover study to investigate the pharmacokinetics of amoxycillin after single intravenous and oral doses of 20 mg/kg bodyweight. Twelve pigs were used to study the residues of the drug in muscle, kidney, liver and fat after they had received daily oral doses...

  • Remission of primary pulmonary hypertension during treatment with diazoxide.  // British Medical Journal (Clinical Research Edition);4/4/1981, Vol. 282 Issue 6270, p1118 

    Examines pulmonary hypertension during treatment with diazoxide. Reduction of pulmonary vascular resistance; Administration of intravenous injections of isoprenaline and tolazoline; Effectiveness of diazoxide.

  • Intravenous administration sets.  // Journal of Perioperative Practice;Mar2006, Vol. 16 Issue 3, p112 

    The article identifies the optimal interval for the routine replacement of intravenous administration sets when infusate or parenteral nutrition solutions are administered to people in hospital via central or peripheral venous catheters. Intravenous administration is a common occurrence within...

  • Make room for new IVIG-this one from a foreign firm. Magill-Lewis, Jillene // Drug Topics;7/12/2004, Vol. 148 Issue 13, p36 

    This article provides information on the intravenous immune globulins (IVIG or IGIV) drug, Octagam, developed by Octapharma AG. The U.S. Food and Drug Administration approved Octapharma's IVIG product in May 2004 but the firm has been marketing the product in Europe for 10 years. Octagam is...

  • TOWARD IMPECCABLE IV TECHNIQUE. Masoorlie, Susan Thomas // RN;Feb81, Vol. 44 Issue 2, p20 

    Provides guidelines that nurses can use for veripuncture. Tips on choosing the site, vein and device; Anatomy of a vein; Steps in inserting a scalp vein needle; Procedure in inserting an intravenous catheter.

  • Population pharmacokinetics of topotecan: intraindividual variability in total drug. Montazeri, Ashraf; Boucaud, Maude; Lokiec, François; Pinguet, Frédéric; Culine, Stéphane; Déporte-Féty, Régine; Albin, Nicolas; Laguerre, Brigitte; Goupil, Alain; Bugat, Roland; Canal, Pierre; Chatelut, Etienne // Cancer Chemotherapy & Pharmacology;Nov2000, Vol. 46 Issue 5, p375 

    The inter- and intraindividual variabilities in topotecan clearance (CL) were explored using a population pharmacokinetic approach. Total (lactone + hydroxy acid) topotecan plasma concentrations were obtained in 31 women with metastatic epithelial ovarian cancer treated by the 30-min intravenous...

  • P&T PORTFOLIO.  // Drug Topics;3/22/2004, Vol. 148 Issue 6, pHSE8 

    Discusses the use of BabyBig, botulism immune globulin intravenous, for the treatment of infant botulism. Indications approved by the U.S. Food & Drug Administration; Pharmacology; Pharmacokinetics; Contraindications; Dosage and administration; Adverse effects.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics